Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 2/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28217768 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL3037029 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL28768734 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL7954888 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL4949252 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL240375 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL3817371 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL3022478 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL3711324 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 | |
| SCHEMBL3325109 | 1.00 | NAAA (0.67) | NAAAFAAHEPHX1RAD52NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294497-B1 | COMPRISING A TITANIUM COMPOUND, HAVING AT LEAST A TI-HALOGEN BOND AND AN ELECTRON DONER WHICH MAY BE A SUBSTITUTED MALONIC DIESTER, A 1,3-DIETHER OR A SILOXY COMPOUND SUPPORTED ON A MG HALIDE | MONTELL TECHNOLOGY COMPANY BV (NL) | 2001-09-25 | — | — | US | claimed |
| CN-119219664-A | Circularly polarized organic room temperature phosphorescent material and preparation method and application thereof | 香港中文大学（深圳） | 2024-12-31 | — | — | CN | disclosed |
| US-9296685-B2 | Method of producing nanoparticle suspensions | BASF SE (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296685-B2 | Method of producing nanoparticle suspensions | BASF SE (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296685-B2 | Method of producing nanoparticle suspensions | BASF SE (DE) | 2016-03-29 | — | — | US | disclosed |
| CN-102883800-B | Method for producing nanoparticle suspensions | BASF SE (DE) | 2016-03-02 | — | — | CN | disclosed |
| EP-2544811-A1 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS | BASF SE (DE) | 2013-01-16 | — | — | EP | disclosed |
| CN-102883800-A | Method for producing nanoparticle suspensions | BASF SE | 2013-01-16 | — | — | CN | disclosed |
| US-20120329888-A1 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS | BASF SE (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329888-A1 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS | BASF SE (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329888-A1 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS | BASF SE (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2011110990-A1 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS | BASF SE (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110990-A1 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS | BASF SE (DE) | 2011-09-15 | — | — | WO | disclosed |
| EP-1953237-A1 | A method for the production of short chained glycolipids | ECOVER N.V. (AN) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329888-A1 | METHOD OF PRODUCING NANOPARTICLE SUSPENSIONS | C1S, C1R, C9 | NAAA 3222/4885FAAH 279/4885EPHX1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.